Both in Pharmaceuticals
Ocular Therapeutix vs Mineralys Therapeutics
Over the past year OCUL returned −38.9% and MLYS returned −53.6%; their daily moves had a correlation of 0.30.
OCUL −38.9% MLYS −53.6%Growth of $1, one year, split-adjusted
| Metric | OCUL | MLYS |
|---|---|---|
| Price | $6.97 | $18.18 |
| Market cap | $1.53B | $1.61B |
| Today | −4.65% | −14.41% |
| 1 month | −4.4% | −23.4% |
| 6 months | −26.1% | −37.9% |
| Year to date | −42.6% | −49.9% |
| 1 year | −39.3% | −54.7% |
| Revenue growth (YoY) | +0.1% | — |
| Gross margin | 85.1% | — |
| Net margin | −584.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 29.4× | — |
| Net cash | $525.8M | $563.8M |
| Dividend yield | — | — |
| Volatility (60d) | 76.1% | 65.5% |
| Short % of float | 15.1% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).